Summary
Unable to verify any claims against the FDA-approved prescribing information because no label text/sections were provided; all statements are treated as 'absent from the label' for evaluation purposes.
Category Scores
Accurate Statements
Unsupported Statements
Jardiance is the brand name for empagliflozin.
Not verifiable because no label text/sections were provided (classified as absent from the label).
Empagliflozin is a prescription medicine.
Not verifiable because no label text/sections were provided (classified as absent from the label).
Empagliflozin (Jardiance) is FDA-approved for certain uses related to type 2 diabetes.
Not verifiable because no label text/sections were provided (classified as absent from the label).
Depending on the specific indication, empagliflozin (Jardiance) is FDA-approved for heart disease and kidney disease.
Not verifiable because no label text/sections were provided (classified as absent from the label).
Jardiance (empagliflozin) is an SGLT2 inhibitor.
Not verifiable because no label text/sections were provided (classified as absent from the label).
Jardiance lowers blood sugar by reducing glucose reabsorption in the kidneys.
Not verifiable because no label text/sections were provided (classified as absent from the label).
Jardiance increases glucose loss in urine.
Not verifiable because no label text/sections were provided (classified as absent from the label).
The mechanism of SGLT2 inhibitors affects fluid and kidney-related outcomes.
Not verifiable because no label text/sections were provided (classified as absent from the label).
Some FDA indications for SGLT2 inhibitors include cardiovascular and renal endpoints.
Not verifiable because no label text/sections were provided (classified as absent from the label).
SGLT2 inhibitors like Jardiance carry safety warnings that include risks of genital yeast infections.
Not verifiable because no label text/sections were provided (classified as absent from the label).
SGLT2 inhibitors like Jardiance carry safety warnings that include risks of urinary tract infections.
Not verifiable because no label text/sections were provided (classified as absent from the label).
SGLT2 inhibitors like Jardiance carry safety warnings that include risks of dehydration.
Not verifiable because no label text/sections were provided (classified as absent from the label).
SGLT2 inhibitors like Jardiance carry safety warnings that include risks of low blood pressure.
Not verifiable because no label text/sections were provided (classified as absent from the label).
The risk of dehydration or low blood pressure with SGLT2 inhibitors is especially relevant in people on diuretics or with low baseline blood pressure.
Not verifiable because no label text/sections were provided (classified as absent from the label).
SGLT2 inhibitors like Jardiance carry safety warnings that include diabetic ketoacidosis.
Not verifiable because no label text/sections were provided (classified as absent from the label).
Diabetic ketoacidosis can occur with SGLT2 inhibitors like Jardiance even with only moderately elevated blood glucose in some cases.
Not verifiable because no label text/sections were provided (classified as absent from the label).
SGLT2 inhibitors like Jardiance carry safety warnings that include concerns about acute kidney injury in susceptible patients.
Not verifiable because no label text/sections were provided (classified as absent from the label).
Clinicians typically monitor A1C and fasting or home glucose readings after starting and adjusting Jardiance for blood sugar control.
Not verifiable because no label text/sections were provided (classified as absent from the label).
For heart failure or kidney indications where approved, monitoring usually focuses on clinical status.
Not verifiable because no label text/sections were provided (classified as absent from the label).
For heart failure or kidney indications where approved, monitoring usually focuses on kidney function tests.
Not verifiable because no label text/sections were provided (classified as absent from the label).
For heart failure or kidney indications where approved, monitoring usually focuses on safety labs consistent with the indication.
Not verifiable because no label text/sections were provided (classified as absent from the label).
Contradictions
Important Omissions
No label-based evaluation of contraindications, boxed warnings, dosing/administration instructions, drug interactions, or specific population guidance is possible because the prescribing information content/sections were not provided.
Importance:
High
Safety Assessment
Potential Patient Risk:
Low
The evaluation cannot confirm whether the claims align with the FDA label, but no direct contradictions to labeling were identified because label text was not available for comparison.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Verifiable
Primary Issue
No FDA label text/sections were provided; therefore claim support cannot be verified.
Suggested Improvement
Provide the relevant FDA-approved prescribing information sections (Indications and Usage, Dosage and Administration, Contraindications, Warnings and Precautions/Boxed Warning, Adverse Reactions, Drug Interactions, and relevant Use in Specific Populations) so each claim can be mapped to exact label wording.